Insider Transactions in Q2 2019 at Turning Point Therapeutics, Inc. (TPTX)
Insider Transaction List (Q2 2019)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 27
2019
|
Jingrong Jean Cui Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
54,220
+6.09%
|
$271,100
$5.12 P/Share
|
|
May 14
2019
|
Cormorant Asset Management, LP > 10% Shareholder |
BUY
Exercise of conversion of derivative security
|
Indirect |
23,268
+0.74%
|
$46,536
$2.19 P/Share
|
|
Apr 22
2019
|
Cormorant Asset Management, LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
400,000
+11.43%
|
$7,200,000
$18.0 P/Share
|
|
Apr 22
2019
|
Athena Countouriotis President & CEO |
BUY
Open market or private purchase
|
Direct |
12,000
+50.0%
|
$216,000
$18.0 P/Share
|
|
Apr 22
2019
|
Brian Lee Baker SVP of Finance and Admin. |
BUY
Open market or private purchase
|
Direct |
2,800
+50.0%
|
$50,400
$18.0 P/Share
|
|
Apr 22
2019
|
Simeon George Director |
BUY
Open market or private purchase
|
Indirect |
325,000
+14.02%
|
$5,850,000
$18.0 P/Share
|
|
Apr 22
2019
|
Simeon George Director |
BUY
Conversion of derivative security
|
Indirect |
1,667,550
+37.35%
|
-
|
|
Apr 22
2019
|
Carl L Gordon Director |
BUY
Open market or private purchase
|
Indirect |
360,000
+15.08%
|
$6,480,000
$18.0 P/Share
|
|
Apr 22
2019
|
Carl L Gordon Director |
BUY
Conversion of derivative security
|
Indirect |
1,667,550
+37.35%
|
-
|
|
Apr 22
2019
|
Lu Hongbo Director |
BUY
Open market or private purchase
|
Indirect |
60,000
+3.36%
|
$1,080,000
$18.0 P/Share
|
|
Apr 22
2019
|
Lu Hongbo Director |
BUY
Conversion of derivative security
|
Indirect |
1,667,550
+37.35%
|
-
|
|
Apr 22
2019
|
Orbimed Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
360,000
+15.08%
|
$6,480,000
$18.0 P/Share
|
|
Apr 22
2019
|
Orbimed Advisors LLC Director |
BUY
Conversion of derivative security
|
Indirect |
1,667,550
+37.35%
|
-
|
|
Apr 22
2019
|
Glaxosmithkline PLC Director |
BUY
Open market or private purchase
|
Indirect |
325,000
+14.02%
|
$5,850,000
$18.0 P/Share
|
|
Apr 22
2019
|
Glaxosmithkline PLC Director |
BUY
Conversion of derivative security
|
Indirect |
1,667,550
+37.35%
|
-
|